Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients
The Effect of Etanercept in Suppression of the Systemic Inflammatory Response in Hemodialysis Patients
Sponsor: Amgen
Terminated
We were unable to recruit sufficient patients within the confines of our budget considering the restrains on our recruitment criteria
Other terminated trials from Amgen
Other End Stage Renal Disease trials with similar outcome
This PHASE2 trial investigates End Stage Renal Disease and is currently terminated or withdrawn. Amgen leads this study, which shows 9 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jan 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
- Dialysis Clinic, Inc.
- Kaysen, George A., M.D., Ph.D.
For direct contact, visit the study record on ClinicalTrials.gov .